<SEC-DOCUMENT>0001104659-25-057078.txt : 20250606
<SEC-HEADER>0001104659-25-057078.hdr.sgml : 20250606
<ACCEPTANCE-DATETIME>20250606083034
ACCESSION NUMBER:		0001104659-25-057078
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20250605
ITEM INFORMATION:		Submission of Matters to a Vote of Security Holders
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250606
DATE AS OF CHANGE:		20250606

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GLYCOMIMETICS INC
		CENTRAL INDEX KEY:			0001253689
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36177
		FILM NUMBER:		251028962

	BUSINESS ADDRESS:	
		STREET 1:		9708 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		240-243-1201

	MAIL ADDRESS:	
		STREET 1:		9708 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2517051d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:GLYC="http://glycomimetics.com/20250605">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_032_GLYC_glycomimetics.com_20250605 -->
<!-- Field: Set; Name: xdx; ID: xdx_04A_20250605_20250605 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05B_edei%2D%2DEntityCentralIndexKey_0001253689 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-06-05" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-06-05" id="Fact000004" name="dei:EntityCentralIndexKey">0001253689</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="glyc-20250605.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-06-05">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-06-05</xbrli:startDate>
        <xbrli:endDate>2025-06-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, DC 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_900_edei--DocumentType_c20250605__20250605_zLE2XEAdT6zc"><ix:nonNumeric contextRef="AsOf2025-06-05" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d) of <br/>
The Securities
Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report (Date of earliest event reported):&#160;<span id="xdx_907_edei--DocumentPeriodEndDate_c20250605__20250605_zv6bTaOm0fY4"><ix:nonNumeric contextRef="AsOf2025-06-05" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">June 5, 2025</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_908_edei--EntityRegistrantName_c20250605__20250605_zVGwbyRrQhYc"><b><ix:nonNumeric contextRef="AsOf2025-06-05" id="Fact000011" name="dei:EntityRegistrantName">GlycoMimetics,
Inc.</ix:nonNumeric></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 32%">&#160;</td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 32%">&#160;</td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 32%">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><b><span id="xdx_902_edei--EntityIncorporationStateCountryCode_c20250605__20250605_zd6hAIBxZem8" style="font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-06-05" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_909_edei--EntityFileNumber_c20250605__20250605_zz638pYC5aOb" style="font-size: 10pt"><b><ix:nonNumeric contextRef="AsOf2025-06-05" id="Fact000013" name="dei:EntityFileNumber">001-36177</ix:nonNumeric></b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span id="xdx_90D_edei--EntityTaxIdentificationNumber_c20250605__20250605_zIFPkv6AtA6e" style="font-size: 10pt"><b><ix:nonNumeric contextRef="AsOf2025-06-05" id="Fact000014" name="dei:EntityTaxIdentificationNumber">06-1686563</ix:nonNumeric></b></span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center">(State or other jurisdiction of incorporation)</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">(Commission File Number)</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">(IRS Employer<br/>
    Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_90C_edei--EntityAddressAddressLine1_c20250605__20250605_zVyZLFW42lL6"><b><ix:nonNumeric contextRef="AsOf2025-06-05" id="Fact000015" name="dei:EntityAddressAddressLine1">P.O.
Box 65</ix:nonNumeric></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_90B_edei--EntityAddressCityOrTown_c20250605__20250605_zMRCPaZ3LUnj"><b><ix:nonNumeric contextRef="AsOf2025-06-05" id="Fact000016" name="dei:EntityAddressCityOrTown">Monrovia</ix:nonNumeric></b></span><b>,
<span id="xdx_905_edei--EntityAddressStateOrProvince_c20250605__20250605_zetOZ5h9hEai"><ix:nonNumeric contextRef="AsOf2025-06-05" format="ixt-sec:stateprovnameen" id="Fact000017" name="dei:EntityAddressStateOrProvince">Maryland</ix:nonNumeric></span></b><b>&#160;<span id="xdx_90A_edei--EntityAddressPostalZipCode_c20250605__20250605_z5SbT1Flwr9b"><ix:nonNumeric contextRef="AsOf2025-06-05" id="Fact000018" name="dei:EntityAddressPostalZipCode">21770</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices, including
zip code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_909_edei--CityAreaCode_c20250605__20250605_zHX05PxCpeTb"><ix:nonNumeric contextRef="AsOf2025-06-05" id="Fact000019" name="dei:CityAreaCode">240</ix:nonNumeric></span></b><b>)
<span id="xdx_90C_edei--LocalPhoneNumber_c20250605__20250605_zho5115tuJQ8"><ix:nonNumeric contextRef="AsOf2025-06-05" id="Fact000020" name="dei:LocalPhoneNumber">243-1201</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&#8217;s telephone number, including
area code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>N/A</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Former name or former address, if changed since last report)</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.25pt; text-indent: -14.25pt"><span id="xdx_904_edei--WrittenCommunications_c20250605__20250605_z2ciwJjjSWPe" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2025-06-05" format="ixt:booleanfalse" id="Fact000021" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span><span style="font-family: Times New Roman, Times, Serif">&#160;</span>Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.25pt; text-indent: -14.25pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.25pt; text-indent: -14.25pt"><span id="xdx_903_edei--SolicitingMaterial_c20250605__20250605_zvvQtiIy9KG9" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2025-06-05" format="ixt:booleanfalse" id="Fact000022" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span><span style="font-family: Times New Roman, Times, Serif">&#160;</span>Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.25pt; text-indent: -14.25pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.25pt; text-indent: -14.25pt"><span id="xdx_906_edei--PreCommencementTenderOffer_c20250605__20250605_ze9gtfgaQy13" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2025-06-05" format="ixt:booleanfalse" id="Fact000023" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span><span style="font-family: Times New Roman, Times, Serif">&#160;</span>Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.25pt; text-indent: -14.25pt"><span id="xdx_907_edei--PreCommencementIssuerTenderOffer_c20250605__20250605_zdCaoYcGXM6b" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2025-06-05" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span>
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Securities registered
pursuant to Section 12(b) of the Act:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="padding-right: 5.65pt; padding-left: 5.65pt">&#160;</td>
    <td style="padding-right: 5.65pt; padding-left: 5.65pt">&#160;</td>
    <td style="padding-right: 5.65pt; padding-left: 5.65pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border: black 1pt solid; padding-top: 5pt; padding-bottom: 5pt; text-align: center"><span style="font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 5pt; padding-bottom: 5pt; text-align: center"><span style="font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 5pt; padding-bottom: 5pt; text-align: center"><span style="font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 5pt; padding-bottom: 5pt; text-align: center"><span id="xdx_907_edei--Security12bTitle_c20250605__20250605_zVWnK4xhe5Q1" style="font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-06-05" id="Fact000025" name="dei:Security12bTitle">Common
    Stock, $0.001 par value</ix:nonNumeric></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 5pt; padding-bottom: 5pt; text-align: center"><span id="xdx_90D_edei--TradingSymbol_c20250605__20250605_zjTmWaj2pZ52" style="font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-06-05" id="Fact000026" name="dei:TradingSymbol">GLYC</ix:nonNumeric></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 5pt; padding-bottom: 5pt; text-align: center"><span id="xdx_90C_edei--SecurityExchangeName_c20250605__20250605_zDoLDyF378Rg" style="font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-06-05" format="ixt-sec:exchnameen" id="Fact000027" name="dei:SecurityExchangeName">The
    Nasdaq Stock Market</ix:nonNumeric></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <span id="xdx_905_edei--EntityEmergingGrowthCompany_c20250605__20250605_zhbJwWug3k3a" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2025-06-05" format="ixt:booleanfalse" id="Fact000028" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As previously disclosed, on October&#160;28, 2024, GlycoMimetics,&#160;Inc.,
a Delaware corporation (&#8220;GlycoMimetics&#8221; or the &#8220;Company&#8221;), and Crescent Biopharma,&#160;Inc., a Delaware corporation
(&#8220;Crescent&#8221;), entered into an Agreement and Plan of Merger and Reorganization, which agreement was subsequently amended on
February&#160;14, 2025 and April&#160;28, 2025 (as amended, the &#8220;Merger Agreement&#8221;), pursuant to which, among other matters,
and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Gemini Merger Sub Corp., a Delaware corporation
(&#8220;First Merger Sub&#8221;), will merge with and into Crescent, with Crescent continuing as a wholly owned subsidiary of GlycoMimetics
and the surviving corporation of the merger (the &#8220;First Merger&#8221;), and Crescent will merge with and into Gemini Merger Sub
II, LLC, a Delaware limited liability company (&#8220;Second Merger Sub&#8221; and together with First Merger Sub, &#8220;Merger Subs&#8221;),
with Second Merger Sub being the surviving entity of the merger (the &#8220;Second Merger&#8221; and, together with the First Merger,
the &#8220;Merger&#8221;). After the completion of the Merger, Second Merger Sub will change its corporate name to &#8220;Crescent Biopharma
Operating Company, LLC&#8221; and GlycoMimetics will change its name to &#8220;Crescent Biopharma,&#160;Inc.&#8221; The term &#8220;Combined
Company&#8221; when used herein refers to the post-Merger corporate structure including Crescent Biopharma,&#160;Inc. (f/k/a GlycoMimetics,&#160;Inc.)
as the parent entity and Crescent Biopharma Operating Company, LLC as its wholly-owned subsidiary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item&#8201;5.07</b></span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Submission of Matters to a Vote of Security Holders</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the Merger, GlycoMimetics held a special meeting
in lieu of the annual meeting of GlycoMimetics stockholders on June&#160;5, 2025 (the &#8220;Special Meeting&#8221;), at which the Company&#8217;s
stockholders voted on the proposals set forth below relating to the Merger Agreement. The proposals are described in detail in the Company&#8217;s
definitive proxy statement/prospectus filed on Form&#160;S-4 with the Securities and Exchange Commission (the &#8220;SEC&#8221;), most
recently amended on May&#160;12, 2025 and declared effective on May&#160;14, 2025 (as amended, the &#8220;Proxy Statement&#8221;) and
first mailed to the Company&#8217;s stockholders on May&#160;14, 2025. The final voting results regarding each proposal are set forth
below. There were 64,532,091 shares of the Company&#8217;s common stock outstanding and entitled to vote on May&#160;13, 2025, the record
date for the Special Meeting, and 48,584,725 shares of the Company&#8217;s common stock were represented in person or by proxy at the
Special Meeting, which number constituted a quorum.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Proposal
No.&#160;1</i></b></span><i>: To approve (i)&#160;the issuance of shares of GlycoMimetics common stock (including the shares of GlycoMimetics
common stock issuable upon conversion of GlycoMimetics Series&#160;A Preferred Stock), which will represent more than 20% of the shares
of GlycoMimetics common stock outstanding immediately prior to the Merger, to stockholders of Crescent, pursuant to the terms of the Merger
Agreement, a copy of which is attached as Annex A, including the amendments thereto, to the Proxy Statement, and (ii)&#160;the change
of control of GlycoMimetics resulting from the Merger, pursuant to Nasdaq Listing Rules&#160;5635(a)&#160;and 5635(b), respectively (the
&#8220;Nasdaq Stock Issuance Proposal&#8221;).</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This proposal was approved by the requisite vote of the Company&#8217;s
stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 24%; text-align: center"><span style="font-size: 10pt"><b>For</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 24%; text-align: center"><span style="font-size: 10pt"><b>Against</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 24%; text-align: center"><span style="font-size: 10pt"><b>Abstain</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 25%; text-align: center"><span style="font-size: 10pt"><b>Broker Non-Votes</b></span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">37,164,046</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">625,746</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">23,037</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">10,771,896</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Proposal No.&#160;2</i></b><i>: To approve an amendment to the
amended and restated certificate of incorporation of GlycoMimetics, as amended (the &#8220;GlycoMimetics Charter&#8221;), to increase
the number of shares of GlycoMimetics common stock that GlycoMimetics is authorized to issue from 150,000,000 shares to 175,000,000, in
the form attached as Annex G to the Proxy Statement (the &#8220;Authorized Share Increase Proposal&#8221;).</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This proposal was approved by the requisite vote
of the Company&#8217;s stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 24%; text-align: center"><span style="font-size: 10pt"><b>For</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 24%; text-align: center"><span style="font-size: 10pt"><b>Against</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 24%; text-align: center"><span style="font-size: 10pt"><b>Abstain</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 25%; text-align: center"><span style="font-size: 10pt"><b>Broker Non-Votes</b></span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">47,521,266</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">1,046,614</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">16,845</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">0</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Proposal No.&#160;3</i></b><i>: To approve an amendment to the
GlycoMimetics Charter to effect a reverse stock split of GlycoMimetics&#8217; issued and outstanding common stock at a ratio in the range
between 70:1 to 110:1, inclusive, in the form attached as Annex H to the Proxy Statement, with the final ratio and effectiveness of such
amendment and the abandonment of such amendment to be mutually agreed by the GlycoMimetics board of directors and the Crescent board of
directors prior to the First Effective Time or, if the Nasdaq Stock Issuance Proposal is not approved by GlycoMimetics stockholders, determined
solely by the GlycoMimetics board of directors (the &#8220;Reverse Stock Split Proposal&#8221;).</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This proposal was approved by the requisite vote
of the Company&#8217;s stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 24%; text-align: center"><span style="font-size: 10pt"><b>For</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 24%; text-align: center"><span style="font-size: 10pt"><b>Against</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 24%; text-align: center"><span style="font-size: 10pt"><b>Abstain</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 25%; text-align: center"><span style="font-size: 10pt"><b>Broker Non-Votes</b></span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">47,360,482</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">1,209,020</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">15,223</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">0</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Proposal No.&#160;4</i></b><i>: To approve (A)&#160;the redomestication
of GlycoMimetics from the State of Delaware to the Cayman Islands by conversion (&#8220;Proposal No.&#160;4A&#8221;) and (B)(i)&#160;the
redomestication of GlycoMimetics from the State of Delaware to the Cayman Islands by way of continuation and (ii)&#160;the adoption of
the memorandum and articles of association of the Combined Company, substantially in the form attached as Annex J to the Proxy Statement
(&#8220;Proposal No.&#160;4B&#8221; and together with Proposal No.&#160;4A,&#8220;Proposal No.&#160;4&#8221;).</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This proposal was approved by the requisite vote
of the Company&#8217;s stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 24%; text-align: center"><span style="font-size: 10pt"><b>For</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 24%; text-align: center"><span style="font-size: 10pt"><b>Against</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 24%; text-align: center"><span style="font-size: 10pt"><b>Abstain</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 25%; text-align: center"><span style="font-size: 10pt"><b>Broker Non-Votes</b></span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">34,035,425</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">3,762,361</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">15,043</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">10,771,896</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Proposal No.&#160;5</i></b><i>: To elect Patricia Andrews to
the GlycoMimetics board of directors and to hold office until GlycoMimetics&#8217; annual meeting of stockholders in 2028, and until her
successor has been duly elected and qualified, or until her earlier death, resignation or removal, provided that if the Merger is consummated,
the approval of Proposal No.&#160;5 will only have an effect until the completion of the Merger because the composition of the GlycoMimetics
board of directors will be reconstituted upon completion of the Merger, in accordance with the Merger Agreement.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ms.&#160;Andrews was elected by the requisite
vote of the Company&#8217;s stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 24%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 24%; text-align: center"><span style="font-size: 10pt"><b>For</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 24%; text-align: center"><span style="font-size: 10pt"><b>Withheld</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 25%; text-align: center"><span style="font-size: 10pt"><b>Broker Non-Votes</b></span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Patricia Andrews </span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">31,665,447</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">6,147,382</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">10,771,896</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Proposal No.&#160;6</i></b><i>: To ratify the appointment of
Ernst&#160;&amp; Young LLP as GlycoMimetics&#8217; independent registered public accounting firm for fiscal year ending December&#160;31,
2025, provided that PricewaterhouseCoopers LLP is expected to be appointed for that fiscal year if the Merger is completed, as the Combined
Company&#8217;s independent registered public accounting firm.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This proposal was approved by the requisite vote
of the Company&#8217;s stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 24%; text-align: center"><span style="font-size: 10pt"><b>For</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 24%; text-align: center"><span style="font-size: 10pt"><b>Against</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 24%; text-align: center"><span style="font-size: 10pt"><b>Abstain</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 25%; text-align: center"><span style="font-size: 10pt"><b>Broker Non-Votes</b></span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">48,165,211</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">397,377</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">22,137</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">0</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Proposal No.&#160;7</i></b><i>: To approve
the Crescent Biopharma,&#160;Inc. 2025 Stock Incentive Plan.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This proposal was approved by the requisite vote
of the Company&#8217;s stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 24%; text-align: center"><span style="font-size: 10pt"><b>For</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 24%; text-align: center"><span style="font-size: 10pt"><b>Against</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 24%; text-align: center"><span style="font-size: 10pt"><b>Abstain</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 25%; text-align: center"><span style="font-size: 10pt"><b>Broker Non-Votes</b></span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">27,858,311</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">9,923,826</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">30,692</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">10,771,896</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Proposal No.&#160;8</i></b><i>: To approve
the Crescent Biopharma,&#160;Inc. 2025 Employee Stock Purchase Plan.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This proposal was approved by the requisite vote
of the Company&#8217;s stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 24%; text-align: center"><span style="font-size: 10pt"><b>For</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 24%; text-align: center"><span style="font-size: 10pt"><b>Against</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 24%; text-align: center"><span style="font-size: 10pt"><b>Abstain</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 25%; text-align: center"><span style="font-size: 10pt"><b>Broker Non-Votes</b></span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">36,019,480</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">1,730,643</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">62,706</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">10,771,896</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Proposal No.&#160;9</i></b><i>: To approve, on an advisory basis,
certain compensation arrangements for GlycoMimetics&#8217; named executive officers that are based on or otherwise relate to the Merger.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This proposal was approved by the requisite vote
of the Company&#8217;s stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 24%; text-align: center"><span style="font-size: 10pt"><b>For</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 24%; text-align: center"><span style="font-size: 10pt"><b>Against</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 24%; text-align: center"><span style="font-size: 10pt"><b>Abstain</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 25%; text-align: center"><span style="font-size: 10pt"><b>Broker Non-Votes</b></span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">36,122,320</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">1,653,775</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">36,734</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">10,771,896</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Proposal No.&#160;10</i></b><i>: To approve,
on an advisory basis, the compensation of GlycoMimetics&#8217; named executive officers.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This proposal was approved by the requisite vote
of the Company&#8217;s stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 24%; text-align: center"><span style="font-size: 10pt"><b>For</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 24%; text-align: center"><span style="font-size: 10pt"><b>Against</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 24%; text-align: center"><span style="font-size: 10pt"><b>Abstain</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 25%; text-align: center"><span style="font-size: 10pt"><b>Broker Non-Votes</b></span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">36,536,401</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">1,241,502</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">34,926</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">10,771,896</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 1in"><b>Item 7.01</b></td><td><b>Regulation FD Disclosure</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On June&#160;5, 2025, GlycoMimetics issued a
press release titled &#8220;GlycoMimetics Stockholders Approve Proposed Merger with Crescent and All Related Proposals.&#8221; A copy
of the press release is being furnished as Exhibit&#160;99.1 to this Current Report on Form&#160;8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The information under Item 7.01 of this Current
Report on Form&#160;8-K (including Exhibit&#160;99.1) is intended to be furnished and shall not be deemed &#8220;filed&#8221; for purposes
of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities
of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange
Act, except as expressly set forth by specific reference in such filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 8.01 Other Events.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">At the Special Meeting on June&#160;5, 2025, GlycoMimetics&#8217;
stockholders approved the Reverse Stock Split Proposal. Following this approval, GlycoMimetics&#8217; board of directors approved the
reverse stock split of GlycoMimetics&#8217; issued and outstanding common stock at a final ratio, agreed to by Crescent, of 1-for-100
shares of GlycoMimetics common stock (the &#8220;Reverse Stock Split&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Prior to the closing of the Merger, GlycoMimetics
will file a certificate of amendment to the GlycoMimetics Charter with the Secretary of State of the State of Delaware to effect the Reverse
Stock Split. Upon the effectiveness of such amendment (the &#8220;Reverse Stock Split Effective Time&#8221;), each 100 shares of GlycoMimetics
common stock outstanding immediately prior to the Reverse Stock Split Effective Time will be combined and reclassified, automatically
and without any action on the part of GlycoMimetics or its stockholders, into one new share of GlycoMimetics common stock. No fractional
shares of common stock will be issued as a result of the Reverse Stock Split. Stockholders of record who otherwise would be entitled to
receive fractional shares because they hold a number of pre-split shares not evenly divisible by the number of pre-split shares for which
each post-split share is to be reclassified, will be entitled to a cash payment in lieu thereof at a price equal to the fraction of a
share to which the stockholder would otherwise be entitled multiplied by the closing price of the Company&#8217;s common stock on Nasdaq
on the date of the filing of the amendment to the GlycoMimetics Charter effecting the Reverse Stock Split.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Reverse Stock Split is expected to reduce
the number of GlycoMimetics&#8217; outstanding common stock from approximately 64.5 million shares to approximately 0.6 million shares
of common stock. The number of shares of GlycoMimetics&#8217; authorized common stock will not be affected by the Reverse Stock Split.
At the Special Meeting, GlycoMimetics&#8217; stockholders approved an increase in the number of shares of GlycoMimetics&#8217; authorized
common stock from 150,000,000 to 175,000,000 shares in connection with closing of the Merger. The par value per share of the common stock
will remain unchanged.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In addition, effective as of the Reverse Stock
Split Effective Time and as a result of the Reverse Stock Split, proportionate adjustments will be made to the per share exercise price
and the number of shares issuable upon the exercise, vesting or settlement of all outstanding options to purchase shares of GlycoMimetics
common stock, and the number of shares reserved for issuance pursuant to GlycoMimetics&#8217; existing equity incentive and employee stock
purchase plans will be reduced proportionately based on the Reverse Stock Split.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Following the Reverse Stock Split Effective Time
and consummation of the Merger, the Combined Company&#8217;s common stock is expected to commence trading on a split-adjusted, post-Merger
basis on Nasdaq under the name &#8220;Crescent Biopharma,&#160;Inc.&#8221; and ticker symbol &#8220;CBIO&#8221; at the open of trading
on June&#160;16, 2025, at which time the common stock will be represented by a new CUSIP number (38000Q201) and ISIN Number (US38000Q2012).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Following the closing of the Merger, the Combined Company&#8217;s total
issued and outstanding common stock is expected to be approximately 14.8 million shares, or approximately 25.3 million shares on a fully-diluted
basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 1in"><b>Item 9.01</b></td><td><b>Financial Statements and Exhibits</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(d)&#160;Exhibits</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; white-space: nowrap; font-size: 10pt; width: 8%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit<br/>
Number</b></span></td>
    <td style="padding-bottom: 1pt; vertical-align: bottom; font-size: 10pt; width: 2%; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 10pt; width: 90%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit Description</b></span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><a href="tm2517051d1_ex99-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></a></td>
    <td style="vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt"><a href="tm2517051d1_ex99-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release issued by GlycoMimetics, Inc. on June 5, 2025, furnished herewith.</span></a></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (formatted as Inline XBRL)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Forward-Looking Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certain statements in this Current Report on Form&#160;8-K, other than
purely historical information, may constitute &#8220;forward-looking statements&#8221; within the meaning of the federal securities laws,
including for purposes of the &#8220;safe harbor&#8221; provisions under the Private Securities Litigation Reform Act of 1995, concerning
GlycoMimetics, Crescent, the proposed pre-closing financing and the proposed Merger between GlycoMimetics and Crescent (collectively,
the &#8220;Proposed Transactions&#8221;) and other matters. These forward-looking statements include, but are not limited to: expectations
related to anticipated timing of the closing of the Merger and satisfaction (or waiver) of closing conditions under the Merger Agreement;
the Combined Company&#8217;s listing on Nasdaq after the closing of the proposed Merger; the number of shares of GlycoMimetics common
stock that may be outstanding as a result of the Reverse Stock Split; expectations regarding the ownership structure of the Combined Company;
and the expected executive officers and directors of the Combined Company. In addition, any statements that refer to projections, forecasts
or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The
words &#8220;opportunity,&#8221; &#8220;potential,&#8221; &#8220;can,&#8221; &#8220;goal,&#8221; &#8220;strategy,&#8221; &#8220;target,&#8221;
&#8220;anticipate,&#8221; &#8220;achieve,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221;
&#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;project,&#8221;
&#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions (including the negatives of these terms or variations
of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.
These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects.
There can be no assurance that future developments affecting GlycoMimetics, Crescent, the Proposed Transactions, or the Reverse Stock
Split will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which
are beyond the control of GlycoMimetics and Crescent) or other assumptions that may cause actual results, outcomes or performance to be
materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are
not limited to, the risk that the conditions to the closing or consummation of the Proposed Transactions are not satisfied; the risk that
the proposed pre-closing financing is not completed in a timely manner or at all; uncertainties as to the timing of the consummation of
the Proposed Transactions and the ability of each of GlycoMimetics and Crescent to consummate the transactions contemplated by the Proposed
Transactions; risks related to GlycoMimetics&#8217;s continued listing on Nasdaq until closing of the Proposed Transactions and the Combined
Company&#8217;s ability to remain listed following the Proposed Transactions; risks related to GlycoMimetics&#8217;s and Crescent&#8217;s
ability to correctly estimate their respective operating expenses and expenses associated with the Proposed Transactions, as applicable,
as well as uncertainties regarding the impact any delay in the closing of any of the Proposed Transactions would have on the anticipated
cash resources of the resulting Combined Company upon closing and other events and unanticipated spending and costs that could reduce
the Combined Company&#8217;s cash resources; the failure or delay in obtaining required approvals from any governmental or quasi-governmental
entity necessary to consummate the Proposed Transactions; the occurrence of any event, change or other circumstance or condition that
could give rise to the termination of the business combination between GlycoMimetics and Crescent; costs related to the Merger; as a result
of adjustments to the exchange ratio, Crescent stockholders and GlycoMimetics stockholders could own more or less of the Combined Company
than is currently anticipated; the outcome of any legal proceedings that may be instituted against GlycoMimetics, Crescent or any of their
respective directors or officers related to the Merger Agreement or the transactions contemplated thereby; unexpected costs, charges or
expenses resulting from the Proposed Transactions; potential adverse reactions or changes to business relationships resulting from the
announcement or completion of the Proposed Transactions; and those uncertainties and factors more fully described in filings with the
SEC, including reports filed on Form&#160;10-K, 10-Q and 8-K, in other filings that GlycoMimetics makes and will make with the SEC in
connection with the proposed Merger, including the Proxy Statement, as well as discussions of potential risks, uncertainties, and other
important factors included in other filings by GlycoMimetics from time to time, any risk factors related to GlycoMimetics or Crescent
made available to you in connection with the Proposed Transactions, as well as risk factors associated with companies, such as Crescent,
that operate in the biopharma industry. Should one or more of these risks or uncertainties materialize, or should any of GlycoMimetics&#8217;s
or Crescent&#8217;s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking
statements. Nothing in this Current Report on Form&#160;8-K should be regarded as a representation by any person that the forward-looking
statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved.
You should not place undue reliance on forward-looking statements in this Current Report on Form&#160;8-K, which speak only as of the
date they are made and are qualified in their entirety by reference to the cautionary statements herein. Neither GlycoMimetics nor Crescent
undertakes or accepts any duty to release publicly any updates or revisions to any forward-looking statements. This Current Report on
Form&#160;8-K does not purport to summarize all of the conditions, risks and other attributes of an investment in GlycoMimetics or Crescent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>No Offer or Solicitation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Current Report on Form&#160;8-K and the information contained
herein is not intended to and does not constitute (i)&#160;a solicitation of a proxy, consent or approval with respect to any securities
or in respect of the Proposed Transactions or (ii)&#160;an offer to sell or the solicitation of an offer to subscribe for or buy or an
invitation to purchase or subscribe for any securities pursuant to the Proposed Transactions or otherwise, nor shall there be any sale,
issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except
in accordance with the requirements of the Securities Act of 1933, as amended, or an exemption therefrom. Subject to certain exceptions
to be approved by the relevant regulators or certain facts to be ascertained, no public offer will be made directly or indirectly, in
or into any jurisdiction where to do so would constitute a violation of the laws of such jurisdiction, or by use of the mails or by any
means or instrumentality (including without limitation, facsimile transmission, telephone and the internet) of interstate or foreign commerce,
or any facility of a national securities exchange, of any such jurisdiction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NEITHER THE SEC NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR
DISAPPROVED OF THE SECURITIES OR DETERMINED IF THIS CURRENT REPORT ON FORM&#160;8-K IS TRUTHFUL OR COMPLETE.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 6 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLYCOMIMETICS,&#160;INC.</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: June 6, 2025</span></td>
    <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </span></td>
    <td style="border-bottom: black 1pt solid; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;/s/ Brian Hahn</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian Hahn</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Financial Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KwjAMhZ9g7xB6PbQrKrJLhw5xigwRb6uLUtyakda/R/ItrRtiCITknC9HiFjktDA1MhxmZQE7bNpae4QSz8hoTxgc2XKVQpglXozzrK3v1h+YUWAwMJOBPIZ757wbh1UKcjRU06Eag1TpaALbtYi+ekb2bCq03ugatK1gy9SyQa/51X/Y6SdZal5d0h7ZGbIpJAPZy29QMlGwobt+EF8dFEUmorirSORMtza45k+P9kvCvMYmxLme/nf0Ac5GSmE= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2517051d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>GlycoMimetics
Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&mdash;</B></FONT><I>GlycoMimetics
Board of Directors approves 1-for-100 reverse stock split</I><B>&mdash;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ROCKVILLE, Md.</B>, June 5, 2025 &ndash; GlycoMimetics, Inc. (Nasdaq:
GLYC) (&ldquo;GlycoMimetics&rdquo;) today announced that its stockholders have approved the proposed merger (the &ldquo;Merger&rdquo;)
with Crescent Biopharma, Inc. (&ldquo;Crescent&rdquo;), along with all proposals related to the Merger. The proposals were voted upon
at GlycoMimetics&rsquo; special meeting in lieu of the annual meeting of stockholders held on June 5, 2025 (the &ldquo;Special Meeting&rdquo;),
including a reverse stock split of GlycoMimetics&rsquo; common stock to be effected at the discretion of the board of directors of GlycoMimetics
(the &ldquo;Board&rdquo;) within the parameters approved by GlycoMimetics&rsquo; stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June 5, 2025, following the Special Meeting, the Board approved
a reverse stock split of GlycoMimetics&rsquo; common stock at a ratio of 1-for-100. Following the anticipated closing of the Merger, the
combined company&rsquo;s common stock is expected to begin trading on a post-reverse stock split basis on The Nasdaq Capital Market (&ldquo;Nasdaq&rdquo;)
on June 16, 2025, under the new name &ldquo;Crescent Biopharma, Inc.&rdquo;, ticker symbol &ldquo;CBIO&rdquo;, CUSIP number 38000Q201
and ISIN number US38000Q2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The reverse stock split is expected to reduce the number of GlycoMimetics&rsquo;
outstanding common stock from approximately 64.5 million shares to approximately 0.6 million shares. The number of shares of GlycoMimetics&rsquo;
authorized common stock will not be affected by the reverse stock split. At the Special Meeting, GlycoMimetics&rsquo; stockholders approved
an increase in the number of shares of GlycoMimetics&rsquo; authorized common stock from 150,000,000 shares to 175,000,000 shares in connection
with the anticipated closing of the Merger. No fractional shares will be issued if, as a result of the reverse stock split, a stockholder
would otherwise become entitled to a fractional share because the number of shares of GlycoMimetics common stock they hold before the
reverse stock split is not evenly divisible by the split ratio. Instead, each stockholder will be entitled to receive a cash payment in
lieu of such fractional share. The cash payment to be paid will be equal to the fraction of a share to which such stockholder would otherwise
be entitled multiplied by the closing price per share as reported by The Nasdaq Stock Market LLC on June 12, 2025, the trading day prior
to the date the charter amendment to effect the reverse stock split is expected to be filed with the Secretary of State of the State of
Delaware (with such price proportionately adjusted to give effect to the reverse stock split).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a result of the reverse stock split, proportionate adjustments will
be made to the exercise prices and number of shares of GlycoMimetics&rsquo; common stock underlying GlycoMimetics&rsquo; outstanding equity
awards. There will be no change to the par value per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Following the closing of the Merger, the combined company&rsquo;s total
issued and outstanding common stock is expected to be approximately 14.8 million shares, or approximately 25.3 million shares on a fully-diluted
basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>About GlycoMimetics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">GlycoMimetics is a late clinical-stage biotechnology
company that was previously discovering and developing glycobiology-based therapies for cancers, including AML, and for inflammatory diseases.
The company&rsquo;s scientific approach was based on an understanding of the role that carbohydrates play in cell recognition. Its specialized
chemistry platform can be used to discover small molecule drugs, known as glycomimetics, that alter carbohydrate-mediated recognition
in diverse disease states, including cancers and inflammation. The company&rsquo;s goal was to develop transformative therapies for diseases
with high unmet medical need. Learn more at www.glycomimetics.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>About Crescent Biopharma, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Crescent Biopharma, Inc. is a biotechnology
company advancing novel precision-engineered molecules to advance care for patients with solid tumors. Crescent&rsquo;s pipeline of three
programs harnesses validated biology to accelerate the path to market for potentially best-in-class therapeutics. Crescent&rsquo;s lead
program is CR-001, a tetravalent PD-1 x VEGF bispecific antibody, and it is also advancing CR-002 and CR-003, antibody drug conjugates
with topoisomerase inhibitor payloads for undisclosed targets. For more information, visit www.crescentbiopharma.com and follow Crescent
on LinkedIn.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Forward-Looking Statements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Certain statements in this press release,
other than purely historical information, may constitute &ldquo;forward-looking statements&rdquo; within the meaning of the federal securities
laws, including for purposes of the &ldquo;safe harbor&rdquo; provisions under the Private Securities Litigation Reform Act of 1995, concerning
GlycoMimetics, Crescent, the proposed pre-closing financing and the proposed Merger between GlycoMimetics and Crescent (collectively,
the &ldquo;Proposed Transactions&rdquo;) and other matters. These forward-looking statements include, but are not limited to: expectations
related to anticipated timing of the closing of the Merger and satisfaction (or waiver) of closing conditions under the merger agreement;
the combined company&rsquo;s listing on Nasdaq after the closing of the proposed Merger; the number of shares of GlycoMimetics common
stock that may be outstanding as a result of the reverse stock split; and expectations regarding the ownership structure of the combined
company. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances,
including any underlying assumptions, are forward-looking statements. The words &ldquo;opportunity,&rdquo; &ldquo;potential,&rdquo; &ldquo;can,&rdquo;
 &ldquo;goal,&rdquo; &ldquo;strategy,&rdquo; &ldquo;target,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;achieve,&rdquo; &ldquo;believe,&rdquo;
 &ldquo;contemplate,&rdquo; &ldquo;continue,&rdquo; &ldquo;could,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;intends,&rdquo;
 &ldquo;may,&rdquo; &ldquo;plan,&rdquo; &ldquo;possible,&rdquo; &ldquo;project,&rdquo; &ldquo;should,&rdquo; &ldquo;will,&rdquo; &ldquo;would&rdquo;
and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the
absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations
and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting GlycoMimetics,
Crescent, the Proposed Transactions, or the reverse stock split will be those that have been anticipated. These forward-looking statements
involve a number of risks, uncertainties (some of which are beyond the control of GlycoMimetics and Crescent) or other assumptions that
may cause actual results, outcomes or performance to be materially different from those expressed or implied by these forward-looking
statements. These risks and uncertainties include, but are not limited to, the risk that the conditions to the closing or consummation
of the Proposed Transactions are not satisfied; the risk that the proposed pre-closing financing is not completed in a timely manner or
at all; uncertainties as to the timing of the consummation of the Proposed Transactions and the ability of each of GlycoMimetics and Crescent
to consummate the transactions contemplated by the Proposed Transactions; risks related to GlycoMimetics&rsquo; continued listing on Nasdaq
until closing of the Proposed Transactions and the combined company&rsquo;s ability to remain listed following the Proposed Transactions;
risks related to GlycoMimetics&rsquo; and Crescent&rsquo;s ability to correctly estimate their respective operating expenses and expenses
associated with the Proposed Transactions, as applicable, as well as uncertainties regarding the impact any delay in the closing of any
of the Proposed Transactions would have on the anticipated cash resources of the resulting combined company upon closing and other events
and unanticipated spending and costs that could reduce the combined company&rsquo;s cash resources; the failure or delay in obtaining
required approvals from any governmental or quasi-governmental entity necessary to consummate the Proposed Transactions; the occurrence
of any event, change or other circumstance or condition that could give rise to the termination of the business combination between GlycoMimetics
and Crescent; costs related to the Merger; as a result of adjustments to the exchange ratio, Crescent stockholders and GlycoMimetics stockholders
could own more or less of the combined company than is currently anticipated; the outcome of any legal proceedings that may be instituted
against GlycoMimetics, Crescent or any of their respective directors or officers related to the merger agreement or the transactions contemplated
thereby; unexpected costs, charges or expenses resulting from the Proposed Transactions; potential adverse reactions or changes to business
relationships resulting from the announcement or completion of the Proposed Transactions; and those uncertainties and factors more fully
described in filings with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;), including reports filed on Form 10-K, 10-Q and
8-K, in other filings that GlycoMimetics makes and will make with the SEC in connection with the proposed Merger, including the proxy
statement/prospectus, as well as discussions of potential risks, uncertainties, and other important factors included in other filings
by GlycoMimetics from time to time, any risk factors related to GlycoMimetics or Crescent made available to you in connection with the
Proposed Transactions, as well as risk factors associated with companies, such as Crescent, that operate in the biopharma industry. Should
one or more of these risks or uncertainties materialize, or should any of GlycoMimetics&rsquo; or Crescent&rsquo;s assumptions prove incorrect,
actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this press release should
be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the
contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements
in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary
statements herein. Neither GlycoMimetics nor Crescent undertakes or accepts any duty to release publicly any updates or revisions to any
forward-looking statements. This press release does not purport to summarize all of the conditions, risks and other attributes of an investment
in GlycoMimetics or Crescent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>No Offer or Solicitation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">This press release and the information contained
herein is not intended to and does not constitute (i) a solicitation of a proxy, consent or approval with respect to any securities or
in respect of the Proposed Transactions or (ii) an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation
to purchase or subscribe for any securities pursuant to the Proposed Transactions or otherwise, nor shall there be any sale, issuance
or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except in accordance
with the requirements of the Securities Act of 1933, as amended, or an exemption therefrom. Subject to certain exceptions to be approved
by the relevant regulators or certain facts to be ascertained, no public offer will be made directly or indirectly, in or into any jurisdiction
where to do so would constitute a violation of the laws of such jurisdiction, or by use of the mails or by any means or instrumentality
(including without limitation, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or any facility
of a national securities exchange, of any such jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">NEITHER THE SEC NOR ANY STATE SECURITIES COMMISSION
HAS APPROVED OR DISAPPROVED OF THE SECURITIES OR DETERMINED IF THIS PRESS RELEASE IS TRUTHFUL OR COMPLETE.</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>GlycoMimetics Investor Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Argot Partners</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">212-600-1902</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Glycomimetics@argotpartners.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Crescent Biopharma Investor Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amy Reilly</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Communications Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">amy.reilly@crescentbiopharma.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">617-465-0586</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>glyc-20250605.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaCL6bOdzZR+uYkxtmB8bVkKfyQnOvx76SvzpdC2AccM -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:GLYC="http://glycomimetics.com/20250605" elementFormDefault="qualified" targetNamespace="http://glycomimetics.com/20250605">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://glycomimetics.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="glyc-20250605_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="glyc-20250605_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>glyc-20250605_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>glyc-20250605_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://glycomimetics.com/role/Cover" xlink:href="glyc-20250605.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://glycomimetics.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jun. 05, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun.  05,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GlycoMimetics,
Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001253689<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">06-1686563<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">P.O.
Box 65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Monrovia<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">21770<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">243-1201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GLYC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2517051d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glycomimetics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>glyc-20250605.xsd</File>
    <File>glyc-20250605_lab.xml</File>
    <File>glyc-20250605_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tm2517051d1_8k.htm">tm2517051d1_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm2517051d1_8k.htm": {
   "nsprefix": "GLYC",
   "nsuri": "http://glycomimetics.com/20250605",
   "dts": {
    "schema": {
     "local": [
      "glyc-20250605.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "glyc-20250605_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "glyc-20250605_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2517051d1_8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://glycomimetics.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-05",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2517051d1_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-05",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2517051d1_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://glycomimetics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001104659-25-057078-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-25-057078-xbrl.zip
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MV\/9H-(+,FVK5F .LO!P:7GK@T4%J/6,"O&)2;ZPNA5W@K\D+(*7S)#<"S"
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M;YQN689%_BZYL(U,@,XM.8#-)C&&*"!2[,X 0BHQ*M1^7M NLD=4BZSB=X?
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MJ%X!6JEGQ,HJT!^J$I378OO]\OJF:_E);M:;Y%\KG!*YY;]02P,$%     @
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M22YY<!.-$>M/T=5*0^*PD>N+,$CE-*NU-5#-><QDK'23K&(O-W>%XTP7=D4
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M5J6]U:IL L,?0)GH%&=@?85HD @QA?4PE%!\.%.B"'-)>&;S#<L))@/=44^
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MHUFI-3>7D[9ZK;*Y6:]L;7=^_E"3/. E">!M)( WAW2!,PED4D#)TM8E@A/
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MP]L%AY@OC4U2R1#)SO08HC-V&G.4 Y%/2*4B5\;/ECY,:B1 ,_.2X^OZ-BP
M9;?&FX73R^(SWMM<XEJ=#M65] C7;RB)JD!_N.J9:W8LO=)>FAPBLQ)N1XAS
MP?X,\[LA'^50Y/J3=J-I=J.BTQ?K+EA0L +VFLU@Y*DX9(,2[\W,E'8SF:8/
M++DL$>*:2DG%DHIRJFJW4$I/Q>T^!]?HL5^7"G49J2Z:@-VH*)];8<[#2J%I
MGLUCF-BR6.FBRS/780)[7G C$UJY87+*OKB5PNL(C+:L)[GLU;AVM:*O1T7]
M,3/2?>%LJ() 5V'5M^Z7-VWQ_:+&A4\_BQ"=F=>\(JY0%SZ4INFTQ+T%J%LQ
M_UDVY4;^IE]2?-.OF6Z2LTCELTXN'BN]A4S=S6#(IV4P?YU\FJHLG(5W[!K4
MW75-;/:B6R/K.F9[K*>Y.!8GS+M77KJ[FT\NBK#U56@RZXGMT3!4=VG0&' I
M%1C4FXE<X,AC($"L"CH[NJ_3&L_/+UP$,&%Q]B)>D>4[\!GQ0;Y$GQ?/CW4P
M@,F(R_:H9\RI;-I(U2$]F4-QXS,FK=/#7\"5]2RV@X(RN27F6#96V9L@]ARL
MW,B2*;*2(CM3TO0(&I=XS.3M*-1(Z0(+7U7J(U4<<0:0AA>&..ZU&[IHBRC?
MWX+/$'R(%(&6S!>*B:R- @AR)+;)CJKFDYGP$^8<#:$*.A.2K)/CBDR". -1
M]TWQT"QA>->*%C/=<S%+Y;C@JS3%K3'PBH<I3TT2)IA:$$A/?9Y::<A6[Y70
MU%<71EM*)!UCYBL(H[/]WD^CJ FO,BP62<_/HY$O2K1"[KPS9TYLYW,0%:Z9
MI0NEN/-1+,6W[D3JIDYKO4TF('<H*VG&H6RAVGHG5\;*37&9._?.W$C)?4-I
M J)Y1:&P/15#G(I=T2!;Q9"H!)<4HQ_J)PF>].62/] /:Y[19BZG;!(G7:T[
MGRV[<$56J:(I)P"Z8H8I=U/MK/9EDL8ME6=U@L$JL2\QOO,3S8<^[CTYKC2,
MTF31-"Q<+*S")51<-'JO9:8B-WBX6"8BO+T4W5 RH$?KXPEUDBB<E/?LEG$;
MU:50A):^8W].>+)Y= 5<45]6R#63R5C1_&,1*%Q]_3^:@N8\EE>JBKDYU5'T
M]P$E%5)*%^;AY=?J\H0DH["9,;90YMFM2B"+6U\17LBJ3QZ*; <ZXE_*8D+K
MU*.^>046ZC(GRWIOEH9!_5Q:_3[A@ZW7\,%'#A]\!E5DVKWW@>Y""227TA5<
MYU9TPW$Q9LJM_OA.^%PB3AUE]5-I.U>ERD( *8"FRELMMNU3Z&7XB'"#7EM#
M"P_Q9"Y&=FW<\ IGDV'@)5^_ZY\FA>12'$R9[+6DT\IX)^H=[9Z T@J+HKK.
MKV&&HDASS0,.H,(PZ7T:],^T/EMM;L&*^K%1J\N+L/N#_@DY4>\^#9*WC4<S
MTHL$Y9'525;N2JSTA;(4!1'88_?QGA1>JV. OWIK?2N'_H0+,5NJT5YOYG&D
M$-%1#!9JU7$]O.U0"N63AT#\+3>*M@LVB@Y='Q9M1+[)3>?RZD_E6 ]_EATC
MT<U51]TBGZ7^-5SFGF"AN)Z2"(C<CG)"^]8O1?IM?C-Z1&&VSW;NXDA1[(0:
MWC=#OK%G255]5RB(&I44A2#%9?TMZUJCL&OW#RVY-\/+"-BN/1MSR3ZLZ]P5
M5L."V)3YF)LB62F,69AOG)(Q9Z.W*]&DT:YOUMIUI_Z5W6YO5^OKXVB23*=J
MR.PJ, $]5#NP]@AZ'Y,+N)&8])<^)'*CH+*'AG(L+UO.Q#[V>;*/+:!!/C-;
MA8C3VPJUD60[*=V$1<<CNBK6\RQ^*K%Z- ;4:\\2AOR$/>@%T*(P+6&8(B9\
MO&!Z[-.(@H4%*]JJW)Z/I)>][WL #LD?[\Z/UA:&"2TG'C@,^ WE3O4H"*X0
MMJ889WGW;6&,U#FQ,$5DPJUX=RQ(1;K@,33 1\\)XFKX+ HXRI@9>U&!1D6>
M('6->!(!H3CF*8ZE-&@K#6>N\G).&/4-LV+$8*W#C9(T@L"C-V'%2L,US)@*
M_9EJ.:0C1@#VPY*IFQ(7>X;":Y7:GF?<O48WFQ&G< 1_74IK^9R)O#Y)Y,(V
M:![HI<TX4FKE-%6ZL2O#=%30#^[&:)-I) $R_$N[P::YV""=$32[SX"E$]-X
M%8&;M/*]F;QG/I,#""J[X-0/Y8Z+9K4T1^6(BBG)0^''#47RHI)ADIE('58A
MPUB>#$1ON.=.7&F>[2A;3; KM+@*84*/O0^$NU/Y$\JG UMH/LI8&J@F'*F-
MHE7<LZ+01[XF-O#45\!^Z8LU1S%__?RNM= 8]93','5&T%&DJLI1EQN>W?OY
MXY5%*^,;9&@-3A"P94VS]WX.X=T,B_'R5Q@J;8H'-SZ4'[NH)GAL1S$W=\ R
MO=]-/,*)>5UP A3+I&$2)56MDXQ/'+=X#9$1W15!.<([S(-O<D,!9@@Z]FP:
M1J&E(Y.(#1R$$0?5]5WU$!H=Q:(G3$3%H'%ON]R.)\@YFX4J/Z[D(;0MY,";
M29:&\62J6D-Q+1=M(?S6#4#J4$^?8(IZ,/;=:%;16D.]F@81$RF_\B]L4,"Y
M1Y?!?#$8'FCX<J[>")0UB_132SU-)T^^/+7'+K E_WC(O*+'F!D-/> %%:FD
M:07/8\_)TX.[ I."2J0DY9_*>+DP_QAFP!Q7O7GNP703V]ISSZ4@Y4D+QR;!
MNC#ZZ^:>84'3A1B"6O+P0F@98":$SP@&%#.=X4IPG2PON%//^$3(Y#7EKM)[
M\N5D3<QR%R]IQLNNRV5/JE.QOSP,A1LUJ5X*I!.HS7Y<%-6Q[/1[G<\XU\"Z
M=:<ZSYSMMM7RG]$OR!@A3:/06.KTC'1 R+Q@FCIV@&@7%F$].]3^6"A(@?(P
M.U#K^8&8F5SLZ,A[L8OJ2S;1%RZLA8M<$D58M!FGO;?1. A5^R+=BD@18RQ4
M]UH/KP,/]Y:,18"[X140$/OJ2+Y $:MA,!'#*N,N!./9+% J&&<?#[SYA<-<
MZ->2^$U3KZ7+B8P< 09@G(5<1Y /<61CJD7\>,JXP&B"[>A+M7 6<YFYT'%'
M(G RTKD7D3EJ+J" <.).S$"+A8S1K!.\4'EY3';D<825Q1%R9/%CV3W%([W2
MY\/#>.&F1J%@)*!%@@OHSFZV+>L>8$W-M^2^=A'N*K8*@(_ 7A\%@8O@%\_;
MS76=)O3G<%"V"]:"+B0IV3%@5P2KB3B>A=(C=VET/B+9OEFIL38D,0VZ><ML
M?E<-J@'NBC9B0YV'$XK, RR9SR@'KA;WMO0N?,T&$80BP@JP/;%Q;&Y3%-9^
M[\Z8K-0/+:-E.^"(DC"]E%H<E2Z$;Z9J"PYS!5"Y-WV+YU29K#;]H=*-,B<-
M22S1;O*LIP>&%RZ-%OR\8:#4:)@3MBP\A D,-0B0Y$"'DVREQCC@NX7#(8.Q
MA+Y4&^&&QK1$,!AT.8BYG1IA4AEA"WGHJ/)+J?93BT1!/:DX3-LAG*I\#7(K
M,]0 4^ 4,PBI?!LS0Z*<_2/J>@(K\Y0QP1"YB$V)4[287D$'%JOTM$C_);H\
M?-1YF-6+8T*QT*V:3RT1JS8#[(#9R#"X='XFELBF@/2V7)<E*, F!6\J1 7X
MI\C9P,1*)4I]*=6:9- ERB''J!"M@P"^N'Y&;PYC& STQ<D 3_GN;CMT5PV'
M,9526VS7M&X0'YEQ+*HDTV<65)1THKFR@5'09):(S&O93;"#R"20 ^JIF-LB
MH;#0ER%2;TCL ]/7$#8U '(!U=SW8$9YN$#8C*$@&@LPAI"FF=.H/ A;!E[$
M I%,-I=;AJ(P+"Z>VF*%C$V-7(UXRK6Z",H<SG!!2FP^,69"F* V;,]*U%$Z
M:Y-DS"5RFN(]ZDBXQ9FF(.!*4F5,J98MT1DL ,9J45-@G?H!ZC+=M?D<="7$
MR/4"P4MNW87GZ$Q M@K9$%N_,-]Q(V(H%W$9[!DFZM<:'/1,\Y(+SU@HPLV=
MK(.L7D,/&?SY4;0D_&6H1<3<U/4*4<E*[X1>*>($+,6?1D#Z00\JL?)1> 6>
M")-*Q1PSP;18,?02X;BA'2L#!\.#D]$K0JZ55"M;L'Y ]S'Z2C-2X3AGOJMY
MS[T:61%.$8B_I:=  "]=7=DRC *@)XXEPMWH-:ALL4L*96=!7!2LN'C]U-S(
M$)!?@FVA)P0;9,Q^F%H?EAA-N:@GL9E#':>"*7I P_'9.AF,I5+RA3Z2>DG;
M=Q)^B-R3IK!J7.Y^9\*4D6:M5AB%$,4R>)3"%L-0D(</Q9DM5"^5G*D@5-@U
MKD_0%=V^AB^A:10HTUN.>J$E8)F6P$F /MW+^[J9=5]%> VBES0D7P7;J!5I
M)MB!^9?4&B>7\E)*C/-BJ A=/S$$E1?%(3I-DX&",AI4LTH?X5A@&>;K7K<^
M@Y2JOJ'U %6*K*=.+&Y2<^6Z[2^V-N_IJ)>Q2S!R]$JF$TVB4RU'88Z9L(3D
M7!)I[UF:#%6-J\M%G#UG@%XRI_NT_45C$1O),_X^R5L8=N8*A9"=R+XYDX6G
M+A(*$%=#&X_XA1*>QAK0R^U F=C*DT,>3[$3H<S$JGWXPL>\R,F")FD1[ZRL
M]"6N%K&3P(7=)* :QE'+N-=$,)0]6C',7&6?1Q&L*7$D(; (X<906GU$HE2W
M_<0!I.W7 -+E#B 5>Y8G 3E%-P\*W0"&P':E-EWF'<OB:9M;-+27P#P!CJJ;
M"I>!TO?*;V,>X!8;''K*&SN6JZX*]J)"5#6?Q'3&!?!V)K;^0HWD=6)G@1K4
MHJEU4KIEB6LTT*'?+S2TH>BJFU"!+:LME!"!BP+[<[29Y>*AA+9B8Q3^/XQG
MTNJP0!WIC\R(?00:F8^RU&>"[Q<2GIS5,H^."_-#+(E8*T6_11+6C]W!.D9J
M'RUM4YTD_P:_0\>5Z$YB/?@ +6'=\\0=@OO"XN2?Y$2V.DF*/C0A3Y5;)5FL
ME=TOE[7Y _F+#K!CYNY;)I&7[#CB)X""Z:%[?6&KI$'L&QCQK9E+O#QV366B
M1[QW0]F%^GN$KOJ\'@W54R3##W0^2,F(S'$1:6)Z0B  J:I?:$5(&56BFV'[
MC1A >.. < 7*$V3,&4JNW<#+^!)PBSY!2V9E@DO00719J[(30/2A>HRV.>YU
MR(.@/NYF2F\*>E*,31E]K%2XCE7L 3!$;.4H4WCB"E.G0B+@XW2,*#Q5%H!R
M?1:)'67Q(Y3G?+G8FG0O?1G8SFV\=DY.!Z@]\;I2(KTCV; $[<>H:)?!7.>7
M=ID_.>A?_'IP3N /87N>G)Z3[LEG,KCH7H@GG\[[%_V# >F='A_W!X/^Z0GY
MM3L@W;.S\]/_'NR3TW-KOS](?Q[JJO2'4.'^P<7!^7'_!-[W\7T?JOMT?GYP
M<D'.#\Y.SR\(U'IX>GZ<:G<H<G'^Z>+7PT]'6 .T?G8$M2PM'^^&2YU7N+3<
M<*GDUJOAWJ#__J1[\>G\8+#,H.DLMU3?L9857BYCR0\QNS#'JL;H.XH]M=/H
M2%M4NL34^A,"LZ1C# _O#QDLMB.]C EC3Q7 A23&-494EQY3?;U],G(* SJA
M,HR/?+O2>.1X[/='GT&;]H\/+OJ]@3Y;==);O\>%@7^Y(\;['Z@^=QBE7?OE
M,5FS#SA@1P89JT-A][@*LOFH)+R#;Q8U>N?-DI*HUN:C4H6NQ>;V[D:X0=YQ
M%RK]E8[])Y"4PF>/R-R?F/8S#@#8G0+J3 ]8G<I=HJ>];?$%<-+F+CF5UM$.
M.:)AM"RPZ6<$,0NRR0P8,.4$+-@=<NO<[I+^OOC'U]K6NZ]0 _.EDQ4[*3YC
MO]T>?G-J'VZ^=8_'7[8O-V_?=<Z&'_D'_MO1^*9]ZU[>G \[\=&G:$:O'+IQ
MOM&/^'GD]OH75WYO^U?W\-M5M-^M'X]O)U\^'FP.3Z:4M3X.OF^-@XO;2[OQ
MQX?_?IQ>>G\$W[_S#\WK^O@_GS_]WKTY_NWTW5G_RV9[\V8XKG_Z8'\[_U3K
M'-#+^L64=H^&T6?W/^QJV!CV_JPUXTL:?:A?SK8'LX]THUW_8^-S9^!\H5[;
MJ8TWO[P?]J>_=<^^S!K;'X^]]S?!,/K/P>&6<WCP:0)PA _ !(F^TU;[ZC]G
MVU?7O>OCSY/;HPG;\$>UKMU^/Y@<O)4<V1@&S@S_'D<3;^__ %!+ P04
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M[S\'>_L0%H+V:#PZ#Z\^C)N7!S^UIA+'UXFD)TVCTCI1CJN.P@V*"(G4E:W
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MBA]HNS_(:L$G2OV'9V5Y0S+B"L^5*3_,9)6II"Z<4W>@N3^D.2!;'E20\QU
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M'U!+ 0(4 Q0    ( -!#QEHOF'/V+P,  /$+   1              "  0
M  !G;'EC+3(P,C4P-C U+GAS9%!+ 0(4 Q0    ( -!#QEHD+LV,_ H  '^&
M   5              "  5X#  !G;'EC+3(P,C4P-C U7VQA8BYX;6Q02P$"
M% ,4    " #00\9:\=I1^%@'  #>5P  %0              @ &-#@  9VQY
M8RTR,#(U,#8P-5]P<F4N>&UL4$L! A0#%     @ T$/&6N<]CAE\+   ) \!
M !(              ( !&!8  '1M,C4Q-S U,60Q7SAK+FAT;5!+ 0(4 Q0
M   ( -!#QEJOK.GM9A0  &I(   6              "  <1"  !T;3(U,3<P
E-3%D,5]E>#DY+3$N:'1M4$L%!@     %  4 20$  %Y7      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>tm2517051d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="glyc-20250605.xsd" xlink:type="simple"/>
    <context id="AsOf2025-06-05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
        </entity>
        <period>
            <startDate>2025-06-05</startDate>
            <endDate>2025-06-05</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-06-05" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-06-05" id="Fact000004">0001253689</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-06-05" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-06-05" id="Fact000010">2025-06-05</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-06-05" id="Fact000011">GlycoMimetics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-06-05" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-06-05" id="Fact000013">001-36177</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-06-05" id="Fact000014">06-1686563</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-06-05" id="Fact000015">P.O. Box 65</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-06-05" id="Fact000016">Monrovia</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-06-05" id="Fact000017">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-06-05" id="Fact000018">21770</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-06-05" id="Fact000019">240</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-06-05" id="Fact000020">243-1201</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-06-05" id="Fact000021">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-06-05" id="Fact000022">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-06-05" id="Fact000023">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-06-05" id="Fact000024">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-06-05" id="Fact000025">Common     Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-06-05" id="Fact000026">GLYC</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-06-05" id="Fact000027">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-06-05" id="Fact000028">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
